OSCR Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 2.38%, SMA50 -7.69%, SMA200 -16.65%). The stock’s 14-day RSI is 48.15 (neutral), while the ATR of 0.83 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -42.61% below its high and over 21.96% above its low. Average 10-day trading volume of 7.97 million shares is in line with the 3-month average of 7.60 million, indicating normal recent market interest.

Oscar Health, Inc. generated EPS of -$1.75 over the past year. Five-year average earnings growth is 0.13%. The latest quarter delivered EPS of $2.07. The next quarter is forecast at $1.06. Next year's EPS is expected at $71.51. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 11 Hold ratings, 2 Sell rating and 5 Strong Sell ratings. Price targets range from $35.00 to $10.00. The high target offers 8.76% upside. The low target suggests -68.92% downside. The mean target is $17.20. This offers -46.55% upside. Oscar Health, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 86.49%. The prior quarter beat by 34.58%. Over the last six quarters, Apple has recorded several small beats. These include 12.73% in February 04, 2025.

Oscar Health, Inc. has 223.04 million shares outstanding. The public float is 210.30 million shares, elevated short interest at 29.95% of float. This equals 60.08 million shares. The short ratio is 1.57 days. Institutional investors hold 79.99% of the float. Insiders own 4.03%. Bertolini Mark T holds 7.75 million shares, Thrive Partners VII Growth GP, LLC has 6.34 million shares and Kushner Joshua has 6.34 million shares. Over the past six months, insider transactions show net selling. They sold 777.04 thousand shares across 20 transactions.

Oscar Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $64.59. This means the shares are trading below this model’s fair value.

Oscar Health, Inc. (NYSE:OSCR) closed at $32.18 USD, gaining $0.28 (0.88%) from the previous close of $31.90. The stock is currently within 5% of its 52-week high $10.69 and $33.10. With a market capitalization of about $8.34 billion, Oscar Health, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.34). Key stats such as the average daily volume over the past year has been around 7.59 million shares, in line with its 52-week average. Headquartered in New York City, NY, Oscar Health, Inc. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Mark Thomas Bertolini, the company employs approximately 2,400 people and listed since March 03, 2021. Oscar Health, Inc. operates as a health insurance provider across the United States.

Oscar Health, Inc. trades at a P/E ratio of -84.68, slightly below the S&P 500 average, with a price-to-sales ratio of 0.63 and a price-to-book ratio of 5.77 trading at moderately above to book value. The P/FCF stands at 2.98, also above market averages.

Oscar Health, Inc. (NYSE:OSCR) shares are up 10.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Oscar Health, Inc. trading at a premium to the broader market with a P/E of -84.68. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $14.63, suggesting -54.54% downside. Our AI forecast model points to short-term strength (8.55% over two weeks), a medium-term rise (11.34% over three months), and a longer-term gain (6.46% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Oscar Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.55%, with price expected at $34.93 by July 16, 2026, within a range of $33.08 to $36.68 3-Month Outlook: Projected rise of 11.34%, reaching $35.83 by September 30, 2026, with a range of $34.36 to $37.40. 1-Year Outlook: Projected gain of 6.46%, with price at $34.26 by July 02, 2027, within a range of $32.94 to $35.54.